

SUPPLEMENTARY MATERIAL

Table S1 Summary of studies

Study	ITT, <i>N</i>	Randomized duration, weeks	Posttreatment follow-up, ^a Y/N	Treatment	Background diabetes treatment	Study visits, weeks
Kim et al. ^b	45	15	N	Exenatide QW 0.8 or 2.0 mg (<i>n</i> = 16, 15) Placebo (<i>n</i> = 14)	MET	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Drucker et al. (DURATION-1)	295	30	N	Exenatide QW 2.0 mg (<i>n</i> = 148) Exenatide BID 5 µg (4 wk)→ 10 µg (<i>n</i> = 147)	MET/SU/TZD or any combination of 2 of these agents	1, 2, 3, 4, 6, 10, 14, 18, 22, 26, 30
Davies et al.	216	26	N	Exenatide QW 2.0 mg (<i>n</i> = 111) Insulin detemir QD or BID (<i>n</i> = 105)	MET/MET+SU	4, 8, 12, 18, 26
Iwamoto et al. ^b	29	10	N	Exenatide QW 0.8 mg (<i>n</i> = 10) Exenatide QW 2.0 mg (<i>n</i> = 9) Placebo (<i>n</i> = 10)	BG/SU/TZD/BG+SU/ BG+TZD/SU+TZD	1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Bergental et al. (DURATION-2)	491	26	N	Exenatide QW 2.0 mg (<i>n</i> = 160) SITA 100 mg/day (<i>n</i> = 166) PIO 45 mg/day (<i>n</i> = 165)	MET	1, 2, 4, 6, 10, 14, 18, 22, 26
Diamant et al. (DURATION-3)	456	26	N	Exenatide QW 2.0 mg (<i>n</i> = 233)	MET/MET+SU	1, 2, 4, 8, 14, 18, 22, 26

Study	ITT, <i>N</i>	Randomized duration, weeks	Posttreatment follow-up, ^a Y/N	Treatment	Background diabetes treatment	Study visits, weeks
Inagaki et al.	427	26	N	Insulin glargine 10 IU/d adjusted to achieve target glucose of 4.0–5.5 mmol/L (<i>n</i> = 223) Exenatide QW 2.0 mg (<i>n</i> = 215)	BG alone/BG+TZD/ BG+SU/BG+TZD+SU	1, 2, 4, 8, 12, 20, 26
Blevins et al. (DURATION-5)	252	24	N	Insulin glargine 4 U adjusted to achieve FBG <5.5 mmol/L (<i>n</i> = 212) Exenatide QW 2.0 mg (<i>n</i> = 129)	Drug-naïve/MET/SU/TZD or any combination of these agents	1, 4, 8, 14, 20, 24
Russell-Jones et al. (DURATION-4)	820	26	Y ^a	Exenatide BID 5 µg (4 wk)→10 µg (<i>n</i> = 123) Exenatide QW 2.0 mg (<i>n</i> = 248) MET 2000 mg/day (<i>n</i> = 246) PIO 45 mg/day (<i>n</i> = 163) SITA 100 mg/day (<i>n</i> = 163)	Drug-naïve	1, 2, 4, 8, 12, 16, 20, 26, 36
Buse et al. (DURATION-6)	911	26	Y ^a	Exenatide QW 2.0 mg (<i>n</i> = 461) Liraglutide QD 1.8 mg (<i>n</i> = 450)	MET/SU/MET+SU/MET+PIO	1, 2, 4, 8, 14, 18, 22, 26, 36
Ji et al.	678	26	Y ^{a,c}	Exenatide QW 2.0 mg (<i>n</i> = 340) Exenatide BID 5 µg (4 wk)→	MET/SU/TZD/MET+SU/ MET+TZD/SU+TZD	

Study	ITT, N	Randomized duration, weeks	Posttreatment follow-up,^a Y/N	Treatment	Background diabetes treatment	Study visits, weeks
				10 µg (n = 338)		

BID twice daily, *BG* biguanide, *FBG* fasting blood glucose, *ITT* intention-to-treat, *MET* metformin, *PIO* pioglitazone, *SITA* sitagliptin, *SU* sulfonylurea, *TZD*

thiazolidinedione, *QD* once daily, *QW* once weekly, *wk* week

^a Included 10-week off-treatment follow-up period

^b Not included in multivariate analysis


^c Excluded Japanese sites where patients continued through the extension treatment period

	Exenatide QW (n = 2096)	Exenatide BID (n = 606)	Liraglutide (n = 450)	Sitagliptin (n = 329)	Pioglitazone (n = 328)	Insulin (n = 540)	Metformin (n = 246)	Placebo (n = 23)
therapy								
Diet and exercise	314 (15.0)	46 (7.6)	7 (1.6)	154 (46.8)	159 (48.5)	1 (0.2)	233 (94.7)	6 (26.1)
Insulin	1 (<0.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)	3 (1.2)	0 (0.0)
MET	833 (39.7)	159 (26.2)	129 (28.7)	169 (51.4)	161 (49.1)	326 (60.4)	8 (3.3)	10 (43.5)
MET + insulin	2 (<0.1)	4 (0.7)	0 (0.0)	2 (0.6)	4 (1.2)	1 (0.2)	0 (0.0)	0 (0.0)
MET + other	3 (0.1)	1 (0.2)	1 (0.2)	1 (0.3)	0 (0.0)	0 (0.0)	2 (0.8)	0 (0.0)
MET + SU	700 (33.4)	273 (45.0)	271 (60.2)	0 (0.0)	1 (0.3)	140 (25.9)	0 (0.0)	2 (8.7)
MET + SU + insulin	4 (0.2)	1 (0.2)	2 (0.4)	0 (0.0)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)
MET + SU + other	4 (0.2)	2 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MET + SU + TZD	16 (0.8)	12 (2.0)	1 (0.2)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MET + TZD	124 (5.9)	32 (5.3)	21 (4.7)	0 (0.0)	0 (0.0)	69 (12.8)	0 (0.0)	0 (0.0)
Other	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.6)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)
SU	61 (2.9)	48 (7.9)	17 (3.8)	0 (0.0)	1 (0.3)	0 (0.0)	0 (0.0)	3 (13.0)
SU + other	2 (<0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
SU + TZD	20 (1.0)	17 (2.8)	1 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.3)
SU + TZD + insulin	1 (<0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
TZD	10 (0.5)	11 (1.8)	0 (0.0)	0 (0.0)	1 (0.3)	0 (0.0)	0 (0.0)	1 (4.3)
TZD + other	1 (<0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)

Data are presented as *n* (%) or mean ± standard deviation

BID twice daily, *BP* blood pressure, *bpm* beats per minute, *HbA1c* glycated hemoglobin, *MET* metformin, *QW* once weekly, *RA* renin–angiotensin, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus, *TZD* thiazolidinedione

Fig. S1 (a) Mean \pm SE HR over time and **(b)** LS mean \pm SE HR change from BL to final on-treatment measurement by treatment. *BID* twice daily, *BL* baseline, *bpm* beats per minute, *EOT* end of treatment, *HR* heart rate, *LS* least-squares, *QW* once weekly, *SE* standard error



Week	0	2	4	6	10	14	18	22	26	30	EOT
Exenatide QW, n	2096	1433	1985	424	1979	1837	1193	1644	1570	445	2087
Exenatide BID, n	606	271	564	160	543	524	149	490	424	193	599
Liraglutide, n	450	448	426	8	419	365	369	374	366	73	449
Sitagliptin, n	329	325	315	160	310	296	286	275	227	77	325
Pioglitazone, n	328	327	308	158	298	283	268	258	226	52	328
Insulin, n	540	223	504	29	518	483	286	401	443	95	538
Metformin, n	246	246	233	9	232	223	210	212	154	77	246
Placebo, n	23	23	23	23	23	12	7	0	0	0	23




Fig. S2 Regression for change in HR at treatment end versus baseline HR by treatment. *BID* twice daily, *bpm* beats per minute, *HR* heart rate, *QW* once weekly

